http://www.gotoper.com/publications/ajho/2017/2017may/case-study-pathologic-complete-response-following-a-single-cycle-of-neoadjuvant-chemotherapy
Case Study—Pathologic Complete Response Following a Single Cycle of Neoadjuvant Chemotherapy

August 16, 2018
Isolina R. Rossi, BS; Paolo Gattuso, MD; Katherine B. Kabaker, MD; Andrea Madrigrano, MD; and Katherine A. Kopkash, MD

Introduction

Pathologic complete response (pCR) is a term used to describe the absence of residual cancer on pathologic evaluation following systemic neoadjuvant therapy. The original goals of neoadjuvant therapy in breast cancer treatment were to:

  1. Decrease tumor size for improved breast conservation rates and decreased axillary surgery.
  2. Allow for evaluation of tumor susceptibility to specific treatments.

As neoadjuvant therapies have proved their ability to eradicate disease in the breast and lymph nodes, pCR has become an attainable endpoint for breast cancer treatment in some patients.

There is a high rate of pCR in human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-negative breast cancers treated with neoadjuvant TCH+P (docetaxel [T], carboplatin [C], trastuzumab [H], pertuzumab [P]). The regimen involves 6 cycles of chemotherapy followed by surgery and radiation therapy (RT), if indicated, with trastuzumab therapy continuing for 1 year.

In the literature, pCR has been described to occur following complete neoadjuvant treatment regimens; however, it is not unusual for the protocol to be aborted due to toxic adverse events (AEs). We present 1 case in which overwhelming AEs limited TCH+P to a single cycle, yet resulted in a pCR of a grade II invasive ductal carcinoma.

Methods

Case Presentation
A 64-year-old female with a past medical history significant for endometrial cancer (stage II, status: post total abdominal hysterectomy and bilateral salpingo-oophorectomy with 3 rounds of carboplatin/paclitaxel with RT) in remission since 2013, diabetes, fibromyalgia, spinal fusion, osteoarthritis, and psoriasis presented in January 2016 to Rush University Medical Center Breast Surgery clinic complaining of an enlarging left breast mass.

Review of systems was unremarkable except for the left-breast mass. Physical exam of the left breast revealed a 1.5-cm mobile mass in the 6:00 position, 2.5 cm from the nipple, without skin changes or nipple discharge. There was no palpable lymphadenopathy.

She underwent a subsequent mammogram and ultrasound. On mammogram, the area of abnormality spanned 5 cm. A core biopsy of the mass revealed a poorly differentiated infiltrating ductal carcinoma, grade II. Immunostaining showed the cancer was estrogen-receptor weakly positive (5%), progesterone-receptor 0%, and HER2-positive (3+).

MRI was recommended for further evaluation of the extent of the malignancy since the physical exam and mammogram were discordant; however, the patient was unable to have the MRI performed. CT scans of the chest, abdomen, and pelvis were performed, along with a bone scan, and all were negative for metastatic disease.

The presence of HER2-positive disease made our patient a promising candidate for neoadjuvant chemotherapy with TCH+P. The initial multidisciplinary plan was for TCH+P x 6 cycles, followed by lumpectomy and sentinel lymph node (SLN) biopsy, followed by radiation therapy, with trastuzumab to continue for 1 year.

Cycle 1 of chemotherapy was poorly tolerated with 3 hospitalizations for severe nausea, vomiting, diarrhea, dehydration, and diabetic ketoacidosis. The patient also developed a disseminated rash requiring dermatology consultation. Our patient’s previous carboplatin/ paclitaxel for her endometrial cancer 3 years prior may have contributed to her poor tolerance of TCH+P. Due to these complications, she refused further treatment and was referred for surgical intervention at this time with plans for adjuvant chemotherapy to follow. Physical exam revealed no palpable mass in the breast and a clinically negative axilla.

The multidisciplinary tumor board reviewed her case and agreed her cancer could be appropriately treated with breast conservation therapy (BCT) as opposed to a total mastectomy. BCT is performed in 3 steps: 1) surgical removal of the tumor itself, achieving a pathologically free margin of excision; 2) surgical staging of the axilla either by way of SLN biopsy or axillary dissection; 3) RT to the breast and a portion or all of the regional lymph nodes.

Our patient underwent an uncomplicated left wire-directed segmental mastectomy with SLN biopsy.

Specimen imaging confirmed an intact wire, biopsy clip, and lesion of interest. The pathologic specimen labeled left breast partial mastectomy tissue was an ill-defined white, firm, fibrous area measuring 6 × 7.5 × 1.5 cm associated with focal hemorrhage that corresponded with radiologic calcifications. Evaluation revealed histiocytic reaction, chronic inflammation, fibrosis, and calcifications that were consistent with therapy effect. No residual carcinoma was identified

The specimen labeled left axilla sentinel lymph node was fibroadipose and lymphoid tissue measuring 2.0 × 2.0 × 0.7 cm. The node was negative for carcinoma. Her final breast cancer staging based off of the American Joint Committee on Cancer was ypT0ypN0(sn)cM0 (yp representing postneoadjuvant treatment; sn representing sentinel node; c representing clinical) with a pCR after 1 round of TCH+P.

Discussion

The FDA funded Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) meta-analysis by Cortazar and colleagues suggests several key features of pCR (defined in the study as ypT is, where is represents in situ):

  1. Frequency of pCR is decreased in low-grade HR-positive tumors
  2. Frequency of pCR is highest in HER2-positive, HR-negative aggressive tumors
  3. Frequency of pCR is lowest in HER2-positive, HR-positive tumors.

Attaining pCR, regardless of receptor status, is associated with an increased event-free survival (EFS) of 0.25 (95% CI, 0.18-0.34) and overall survival (OS) of 0.19 (95% CI, 0.12-0.31). The study also notes a greater association with EFS and OS in the eradication of tumors from both the breast and lymph nodes versus eradication from breast tissue alone. Results of the large pooled CTNeoBC analysis also demonstrated that the strength of longterm correlation between pCR and survival is increased by the addition of trastuzumab to the therapy regimen.2

In a thorough analysis of pCR in association with the molecular subtypes of breast cancer, Wang-Lopez and colleagues concluded that pCR functions as a surrogate marker of survival for patients with HER2-positive breast cancer.3 Numerous other reports have also suggested improvement in long-term survival   in patients who attain pCR.4-8 This relationship has gained significant support, so much so that the FDA released a “Guidance for Industry” collection of recommendations, the purpose of which is to encourage the use of pCR as an endpoint to support accelerated approval of trial designs. This guidance was prepared in conjunction with the FDA’s Breast and Gynecological Oncology Group, Office of Hematology and Oncology Products, and Center for Drug Evaluation and Research.9

The neoadjuvant TCH+P regimen has been shown to have a pCR rate between 53% to 69% in HER2-positive, HR-negative cancers, according to the TRYPHAENA study. The primary outcomes of the study were focused on certain neoadjuvant chemotherapy regimens and their AEs, particularly looking at cardiotoxicity for trastuzumab.10 The pCR of neoadjuvant regimens involving trastuzumab has been a focus of several well-regarded studies, including NOAH, CLEOPATRA, and NeoALTTO, which all show similar improved results.11-13 Despite its high success rates for disease eradication, however, TCH+P can have significant toxic AEs for the patient.

AEs often lead to the abortion of neoadjuvant protocols. The TRYPHAENA study revealed TCH+P’s significant AEs: Diarrhea, alopecia, and nausea were reported in >50% of patients. More than 35.5% of patients receiving TCH+P experienced serious AEs, including severe diarrhea, vomiting, and febrile neutropenia. Such effects were witnessed in our patient; she developed severe nausea and diarrhea resulting in multiple hospitalizations for diabetic ketoacidosis, and ultimately in the discontinuation of treatment.10

The primary outcome of the TRYPHAENA study was to assess the tolerability and safety of pertuzumab and trastuzumab given in combination with anthracycline-containing neoadjuvant chemotherapy for HER2-positive breast cancer. This AE was measured using left ventricular ejection fraction. Incidence of systolic dysfunction was found to be low, and secondary findings of increased pCR rates when trastuzumab was added to the regimen further supported its addition to chemotherapy regimens.10 Recent studies confirm that the risk of cardiac toxicity is actually significantly lower in trastuzumab patients than was previously suspected (<6%).14

Studies on the efficacy of reducing the number of neoadjuvant cycles for breast cancer have not been widely published. This case report supports the funding of research to determine the optimum number of TCH-P cycles in HER2-positive neoadjuvant chemotherapy. Of interest, a large 2012 study on the reduction of adjuvant chemotherapy cycles identified no additional benefit of 6 versus 4 cycles of chemotherapy for certain breast cancers. The prospective study randomly assigned 3171 patients to either 4 or 6 cycles of therapy with an average follow-up of 5.3 years. The primary efficacy endpoint was measured as relapse-free survival.15

While this case report cannot independently suggest that fewer cycles of standard neoadjuvant chemotherapy should be used to attain pCR in HER2-positive breast cancers, it is important to document that such examples exist. To further understand the significance of this finding, a prospective multi-institution trial could be performed to randomize patients into treatment groups with varying numbers of neoadjuvant cycles, measure pCR rates per group, and correlate number of cycles with pCR rate. Long-term follow-up measuring disease-free and overall survival rates would be necessary to evaluate of treatment regimens that include decreased cycles of neoadjuvant chemotherapy are a possibility.

Conclusion

In summary, this is the first documented case of pCR following a single cycle of neoadjuvant chemotherapy for HER2-positive breast cancer. Studies suggest that pCR can be used as a surrogate marker for survival in HER2-positive breast cancers.3 Of note, some studies have shown that a reduction of adjuvant chemotherapy cycles is not inferior to standard treatment for certain breast cancers.15

This report suggests that research into fewer than the current standard number of cycles of neoadjuvant therapy may help define the optimal treatment to obtain pCR in HER2-positive breast cancer. We are excited about the future possibilities of research advancement in this area and encourage a randomized prospective multicenter clinical trial exploring this idea.

Affiliations: Isolina R. Rossi is a student at Rush Medical College, Chicago, Illinois. Paolo Gattuso is with the Department of Pathology; Katherine B. Kabaker is with the Department of Medical Oncology; Katherine A. Kopkash and Andrea Madrigrano are with the Department of General Surgery, all at Rush University Medical Center, Chicago, Illinois.
Send correspondence to: Katherine A. Kopkash, MD, Department of Surgery, 1725 W Harrison St, Suite 818, Chicago, IL 60612.
E-mail: katherine_kopkash@rush.edu.
Conflicts of interest and financial disclosures: None.

References

  1. American Joint Committee on Cancer. Breast Cancer Staging, 7th edition. AJCC website. https://cancerstaging.org/references-tools/quickreferences/Documents/BreastMedium.pdf Published 2009. Accessed April 25, 2017.
  2. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeo- BC pooled analysis. Lancet.2014;384(9938):164-172. doi: 10.1016/ S0140-6736(13)62422-8.
  3. Wang-Lopez Q, Chalabi N, Abrial C, et al. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer? Crit Rev Oncol Hematol. 2015;95(1):88-104. doi: 10.1016/j.critrevonc.2015.02.011.
  4. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemo- therapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;(30):96-102.
  5. Bear HD, Anderson S, Brown A, et al; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 2003;21(22):4165-4174.
  6. von Minckwitz G, Untch M, Nüesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 2011;125(1):145-156. doi: 10.1007/s10549-010-1228-x.
  7. Feldman LD, Hortobagyi GN, Buzdar AU, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986;46(5):2578-2581.
  8. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796-1804.  doi:10.1200/JCO.2011.38.8595.
  9. Center for Drug Evaluation and Research. Guidance for industry—pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. FDA website. http://www.fda.gov/down- loads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm305501.pdf. Published October 2014. Accessed August 3, 2016.
  10. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278- 2284. doi: 10.1093/annonc/mdt182.
  11. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemo- therapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised con- trolled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377-384. doi: 10.1016/S0140-6736(09)61964-4.
  12. Swain SM, Ewer MS, Cortés J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist. 2013;18(3):257-264. doi: 10.1634/theoncologist.2012-0448.
  13. Baselga J, Bradbury I, Eidtmann H, et al; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicenter, phase 3 trial. Lancet. 2012;379(9816):633-640. doi: 10.1016/S0140- 6736(11)61847-3.
  14. Tiwari SR, Calhoun B, Abraham J, et al. Efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab
  15. [TCHP] in nonmetastatic HER2+ breast cancer: the Cleveland Clinic experience. Paper presented at: 2015 ASCO Annual Meeting. J Clin Oncol. 2015;33(suppl; abstr 531).
  16. Shulman LN, Cirrincione CT, Berry DA, et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol. 2012;30(33):4071-4076. doi: 10.1200/ JCO.2011.40.6405.